Bakuchiol compositions for treatment of post inflammatory hyperpigmentation

Patent metadata

Field	Value
Publication number	US-9713596-B2
Application number	US-201213365172-A
Country	US
Kind code	B2
Filing date	Feb 2, 2012
Priority date	Feb 2, 2011
Publication date	Jul 25, 2017
Grant date	Jul 25, 2017

Abstract

Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.

First claim

The invention claimed is:

1. A method for alleviating, reducing or treating excess pigmentation in a deep layer of skin resulting from post inflammatory hyperpigmentation derived from acne, the method comprising topically administering to a patient having post inflammatory hyperpigmentation derived from acne an effective amount of a composition comprising from 0.0001% to 2% by weight bakuchiol, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities, thereby alleviating, reducing or treating the excess pigmentation resulting from post inflammatory hyperpigmentation derived from acne in the patient, wherein the composition shows no tyrosinase inhibition activity.

2. The method of claim 1 , wherein the composition comprises less than 100 ppm total furanocoumarin impurities.

3. The method of claim 1 , wherein the furanocoumarin impurities comprise psoralen, isopsoralen or combinations thereof.

4. The method of claim 1 , wherein the composition comprises from about 0.1% to about 2.0% by total weight of bakuchiol.

5. The method of claim 1 , wherein the composition comprises about 0.5% by total weight of bakuchiol.

6. The method of claim 1 , wherein the method alleviates excess pigmentation.

7. The method of claim 1 , wherein the method reduces excess pigmentation.

8. The method of claim 1 , wherein the method treats excess pigmentation.

9. The method of claim 1 , wherein the excess pigmentation occurs in a papillary dermis layer of skin.

10. The method of claim 1 , further comprising reducing super oxide anion.

11. The method of claim 1 , further comprising reducing melanogenesis.

12. The method claim 1 , further comprising reducing melanocyte proliferation.

13. The method of claim 1 , further comprising preventing melanocyte apoptosis.

14. A method for reducing melanogenesis, reducing melanocyte proliferation or reducing melanocyte apoptosis in a deep layer of skin, wherein the melanogenesis, the melanocyte proliferation or the melanocyte apoptosis is a result of post inflammatory hyperpigmentation derived from acne, the method comprising topically administering to a patient having post inflammatory hyperpigmentation derived from acne an effective amount of a composition comprising from 0.0001% to 2% by weight bakuchiol, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities, thereby reducing melanogenesis, reducing melanocyte proliferation or reducing melanocyte apoptosis in the patient, wherein the composition shows no tyrosinase inhibition activity.

15. The method of claim 14 , further comprising reducing super oxide anion.

16. The method of claim 14 , wherein the composition comprises less than 100 ppm total furanocoumarin impurities.

17. The method of claim 14 , wherein the bakuchiol is chemically synthesized or isolated.

18. The method of claim 14 , wherein the furanocoumarin impurities comprise psoralen, isopsoralen or combinations thereof.

19. The method of claim 14 , wherein the composition comprises from 0.1% to 2.0% by total weight of bakuchiol.

20. The method of claim 14 , wherein the composition comprises about 0.5% by total weight of bakuchiol.

21. The method of claim 14 , wherein the method alleviates excess pigmentation.

22. The method of claim 14 , wherein the method reduces excess pigmentation.

23. The method of claim 14 , wherein the method treats excess pigmentation.

24. The method of claim 14 , wherein excess pigmentation occurs in a papillary dermis layer of skin.

25. The method of claim 14 , wherein the method reduces melanogenesis.

26. The method of claim 14 , wherein the method reduces melanocyte proliferation.

27. The method of claim 14 , wherein the method reduces melanocyte apoptosis.

Assignees

• Hong Mei Feng
• Jia Qi
• Brownell Lidia Alfaro
• Unigen Inc

Inventors

• Hong Mei Feng
• Jia Qi
• Brownell Lidia Alfaro

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61P17/10

  Anti-acne agents · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K2800/30

  Characterized by the absence of a particular group of ingredients · CPC title